Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Copeptin: May it be a novel biomarker for insulin theraphy in diabetes? An animal study.

Ece Harman Harman, Yavuz Dodurga, Gulsah Gundogdu, Ceylan Ayada, Gulten Erken, Vural Kucukatay, Cigir Biray Avci, Osman Genc.




Abstract

Copeptin is a marker about prognosis of acute illnesses, generally. It may be also an indicator associated with treatment of chronic diseases. We aimed to evaluate copeptin levels in rat models with stress, diabetes, diabetes+insulin. Healthy male Wistar rats, about 3 months old, weighing 200 –250 g, were obtained from University Animal House. They were housed in small cages at standard conditions (24 ± 2°C and 50 ± 5% humidity) with a 12 h light/dark cycle and were fed ad libitum with standard rat chow and tap water. Rats were divided into 4 groups: 8 control (C), 8 diabetic (D), 8 diabetic+insulin (DI) and 8 stress (S) rats. Quantitative measurement of Copeptin was performed using the ELISA method (Uscn Life Sciences, USA), according to the manufactur er’s instructions. Copeptin level was statistically significant decreased in D+I groups. There was no difference in copeptin level between the S, D, and C groups. Copeptin may be considered as a new tool for the comparison of the efficiencies of new therapeutic modalities in diabetes.

Key words: Key words: Copeptin, insulin, diabetes






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.